2361327-08-2
Chemical Structure
DS44960156
- CAS No.: 2361327-08-2
- Formula:C20H15NO5
- Molecular Weight:349.34
IUPAC Name: 4-(5-oxo-1,3,4,5-tetrahydro-2H-chromeno[3,4-c]pyridine-3-carbonyl)benzoic acid
InChIKey: OXUKTNZACAKVRG-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(C(N2CCC(C3=CC=CC=C3O4)=C(C4=O)C2)=O)C=C1
Biological Activity: DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD+/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DS44960156 | 99.0% | DS44960156 is a selective MTHFD2 inhibitor with moderate to low blood-brain barrier penetration (IC50=1.6 μM, Ki=1.23 μM). DS44960156 specifically binds to the active site of MTHFD2, disrupts redox homeostasis and blocks serine-mediated one-carbon metabolism, thereby increasing the NAD+/NADH ratio and ROS levels. DS44960156 not only effectively inhibits the proliferation of glioma cells, but also enhances the sensitivity of cells to glutamine starvation-induced death. DS44960156 binds to plasma proteins, shows no mutagenicity, carcinogenicity or acute oral toxicity, and serves as a research agent for glioblastoma multiforme and other cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Dekhne AS, et al. Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer. Mol Cancer Ther. 2020 Nov;19(11):2245-2255. [Content Brief]
- [2]. Sun Y, et al. Pharmacological targeting of one‑carbon metabolism as a novel therapeutic strategy for glioblastoma. J Transl Med. 2023 Jun 29;21(1):424. [Content Brief]
- [3]. Alhawarri M B. Schweinfurthiamide as a Promising Anticancer Agent: Molecular Docking, Dynamics, and ADMET Insights Targeting MTHFD2[J]. Journal of Pharmaceutical Innovation, 2025, 20(5): 189.
Keywords
